Lisata Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.93 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.49Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $16.1M Enterprise Value $5.7M Shares Outstanding 10.8M diluted Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Lisata Therapeutics is a clinical-stage pharmaceutical company focused on its proprietary CendR Platform technology, primarily its lead candidate certepetide (LSTA1) for solid tumors. The investment thesis is currently dominated by the active acquisition agreement with Kuva Labs Inc. Under the amended merger agreement, stockholders are positioned to receive $4.00 per share in cash at closing, plus a non-tradeable Contingent Value Right (CVR) worth up to $3.00 per share tied to clinical and regulatory milestones. However, because Kuva Labs lacks committed financing at the commencement of the tender offer, there is execution risk regarding transaction closure, justifying a Hold recommendation to monitor financing progress. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Kuva Labs fails to secure financing, leading to the termination of the merger agreement. Lisata is forced to return to standalone operations with a limited cash runway (approximately $16.0 million as of Dec 31, 2025), requiring highly dilutive equity financing or clinical program cutbacks to survive. Base CaseCentral scenario The acquisition by Kuva Labs closes successfully in Q3 2026. Stockholders receive the $4.00 per share cash consideration, representing a significant premium over historical standalone trading levels, and hold CVRs that provide future upside of up to $3.00 per share as certepetide advances through Phase IIa GBM enrollment and eventual NDA filings. Bull CaseUpside scenario The bull case for Lisata centers on the therapeutic potential of its CendR Platform technology and lead candidate certepetide, which has demonstrated promising clinical data in solid tumors (such as pancreatic cancer and glioblastoma). Additionally, the company maintains a debt-free balance sheet with cash reserves and is owed a $2 million termination fee from Kuva Labs, providing some financial runway as the board explores strategic alternatives (such as a reverse merger or asset sales) to maximize shareholder value. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |